Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Acquisitions & Divestments (2020 - 2025)

Tango Therapeutics has reported Change in Acquisitions & Divestments over the past 6 years, most recently at $39.5 million for Q4 2025.

  • Quarterly results put Change in Acquisitions & Divestments at $39.5 million for Q4 2025, down 53.35% from a year ago — trailing twelve months through Dec 2025 was $224.6 million (down 31.46% YoY), and the annual figure for FY2025 was $224.6 million, down 31.46%.
  • Change in Acquisitions & Divestments for Q4 2025 was $39.5 million at Tango Therapeutics, down from $66.0 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for TNGX hit a ceiling of $109.3 million in Q1 2024 and a floor of $30.4 million in Q3 2021.
  • Median Change in Acquisitions & Divestments over the past 5 years was $64.5 million (2022), compared with a mean of $67.0 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: surged 106.98% in 2022 and later tumbled 53.35% in 2025.
  • Tango Therapeutics' Change in Acquisitions & Divestments stood at $59.9 million in 2021, then surged by 36.94% to $82.0 million in 2022, then rose by 3.79% to $85.1 million in 2023, then decreased by 0.43% to $84.7 million in 2024, then tumbled by 53.35% to $39.5 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $39.5 million (Q4 2025), $66.0 million (Q3 2025), and $41.3 million (Q2 2025) per Business Quant data.